ABSTRACT
BACKGROUND Cardiac resynchronization therapy (CRT) has proven to be an invaluable tool in improving the quality of life in patients with left ventricular dysfunction, conges - tive heart failure, and interventricular conduction delay. Patients who receive CRT have improved functional capacity estimated by 6 minute walk, New York Heart Association classification, and quality of life based on Minnesota Living with Heart Failure questionnaires, and they are protected from the associated increased risk of sudden cardiac death when combined with an implantable cardioverter-defibrillator (ICD) system.1
